Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 2:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Disturbance; Vision, Loss Clear all
Recruiting Phase 1 Interventional

A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

NCT07734064
View directory record Official record
Conditions
Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Interventions
ASP2020
Drug
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Phoenix, Arizona • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Phase 3 Interventional Results available

Effect of Ruboxistaurin on Clinically Significant Macular Edema

NCT00133952
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ruboxistaurin, Placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Phoenix, Arizona • Artesia, California • Newark, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

NCT03927690
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
LKA651, Lucentis
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Idiopathic Intracranial Hypertension Treatment Trial

NCT01003639
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Acetazolamide, Placebo, Formal weight loss counselling program
Drug · Behavioral
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Phase 3 Interventional Results available

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

NCT00604383
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
ruboxistaurin, placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 18, 2026, 2:20 AM EDT
Recruiting Not applicable Interventional

Stem Cell Ophthalmology Treatment Study II

NCT03011541
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Phase 2 Interventional

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Not applicable Interventional

Scotoma Perimetry Oculomotor Training

NCT05456581
View directory record Official record
Conditions
Macular Degeneration, Central Visual Impairment
Interventions
'Scotoma awareness' Training, Control Training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 18, 2026, 2:20 AM EDT
Terminated Phase 4 Interventional

Functional Vision in TBI

NCT01214070
View directory record Official record
Conditions
Brain Injuries, Visually Impaired Persons
Interventions
Vision Restoration Therapy, NVT Eye Scanning Therapy, Eccentric Viewing Training, Sham
Other · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 79 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

NCT04004507
View directory record Official record
Conditions
Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

NCT04503551
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 18, 2026, 2:20 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Factors in Learning And Plasticity: Healthy Vision

NCT05439759
View directory record Official record
Conditions
Central Visual Impairment, Macular Degeneration
Interventions
Condition 1: Training visual sensitivity, Condition 2: Training spatial integration, Condition 3: Training spatial attention, Condition 4: Combination training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Riverside, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 18, 2026, 2:20 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss

NCT06670989
View directory record Official record
Conditions
Central Vision Loss From Macular Diseases
Interventions
Fixation training
Behavioral
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 18, 2026, 2:20 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Emergency Egress and Information System for Persons With Vision Loss

NCT00262509
View directory record Official record
Conditions
Blindness
Interventions
Egress Badge
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 18, 2026, 2:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

First-Sight Refractive Error Correction in the Developing World

NCT01598818
View directory record Official record
Conditions
Vision Loss
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
7 Years to 50 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

NCT06349759
View directory record Official record
Conditions
Mesopic Vision, Night Vision Loss
Interventions
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, Placebo
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
25
States / cities
Pheonix, Arizona • Scottsdale, Arizona • Bakersfield, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

Low Vision Intervention Trial II (LOVIT II)

NCT00958360
View directory record Official record
Conditions
Central Vision Loss From Macular Diseases
Interventions
Interdisciplinary Low Vision Service, Basic Low Vision Service
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Hines, Illinois • Baltimore, Maryland • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

NCT02652780
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 18, 2026, 2:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Virtual Reality Mobility Training System for Veterans With Vision Loss

NCT00333879
View directory record Official record
Conditions
Blindness
Interventions
Virtual Sound System
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 18, 2026, 2:20 AM EDT
Not yet recruiting Not applicable Interventional

Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes

NCT06763952
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes Mellitus
Interventions
AI-BRIDGE, Educational Materials
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
22 Years and older
Enrollment
6,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 18, 2026, 2:20 AM EDT
Recruiting Not applicable Interventional

Developing Evidence-Based Cognitive Approaches to Improve Adjustment to Vision Loss

NCT07073521
View directory record Official record
Conditions
Depression, Anxiety, Visual Impairment, Adjustment, Adjustment Disorder With Anxious Mood, Adjustment Disorder With Depressed Mood, Blindness, Acquired, Blindness and Low Vision, Vision Loss
Interventions
Integrated Cognitive Behavioral Therapy (CBT) & Mindfulness Group Intervention for Adjustment to Vision Loss
Behavioral
Lead sponsor
The Chicago Lighthouse
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 18, 2026, 2:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sight and Hearing Investigation Into Effects on Delirium

NCT06176625
View directory record Official record
Conditions
Hearing Loss, Hearing Loss, Age-Related, Hearing Disability, Delirium, Delirium in Old Age, Delirium of Mixed Origin, Delirium With Dementia, Delirium on Emergence, Delirium, Cause Unknown, Delirium Superimposed on Dementia, Delirium Confusional State, Delirium;Non Alcoholic, Hearing Loss, Bilateral, Hearing Loss, Sensorineural, Hearing Loss, Functional, Hearing Loss, High-Frequency, Hearing
Interventions
Communication Signage, Amplifier Use
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
1,543 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 18, 2026, 2:20 AM EDT
Recruiting Not applicable Interventional

Improving Visual Field Deficits With Noninvasive Brain Stimulation

NCT05085210
View directory record Official record
Conditions
Visual Field Defect, Peripheral, Stroke, Visual Impairment, Hemianopsia, Quadrantanopia, Cortical Blindness, Visual Field Defect Homonymous Bilateral, Occipital Lobe Infarct, Visual Fields Hemianopsia
Interventions
transcranial random noise stimulation (tRNS), Computer Based Visual Training, Sham stimulation, Virtual Reality Based Visual Training
Device · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 18, 2026, 2:20 AM EDT